30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Mineralys Therapeutics Inc (MLYS)

Track

Over the last 90 days, Mineralys Therapeutics Inc. saw a net sale of insider shares totaling approximately $8.76 million. While the total number of transactions was 39, the net buying insider count was -2. Notably, officers like David Malcom and Daphne Karydas engaged in several proposed and planned sales, with transactions occurring throughout May and June.
Stock chart
Ticker: MLYS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Karydas Daphne
2 sales — total 200,000 USD
Planned sale 17 Jun 2026
Value US$4,561,839.73 | Price 218.35 | Shares 78,895
Proposed sale 17 Jun 2026
Value US$3,271,958.68 | Price 249.46 | Shares 48,894
Planned sale 17 Jun 2026
Value US$887,240.13 | Price 205.02 | Shares 10,195
Proposed sale 17 Jun 2026
Value US$4,131,133.59 | Price 331.45 | Shares 70,130
Planned sale 15 Jun 2026
Value US$100,000.00 | Price 23.81 | Shares 1,000
Proposed sale 15 Jun 2026
Value US$100,000.00 | Price 23.81 | Shares 1,000
Planned sale 12 Jun 2026
Value US$100,000.00 | Price 23.93 | Shares 1,000
Proposed sale 12 Jun 2026
Value US$100,000.00 | Price 23.93 | Shares 1,000
Proposed sale 12 Jun 2026
Value US$100,000.00 | Price 23.93 | Shares 1,000
Planned sale 10 Jun 2026
Value US$100,000.00 | Price 25.00 | Shares 1,000
Proposed sale 10 Jun 2026
Value US$100,000.00 | Price 25.00 | Shares 1,000
Planned sale 18 May 2026
Value US$11,488.35 | Price 27.55 | Shares 417
Proposed sale 18 May 2026
Value US$11,488.35 | Price 27.55 | Shares 417
Proposed sale 18 May 2026
Value US$11,488.35 | Price 27.55 | Shares 417
Planned sale 13 May 2026
Value US$401,789.35 | Price 28.58 | Shares 14,056
Proposed sale 13 May 2026
Value US$401,789.92 | Price 28.58 | Shares 14,056
Planned sale 12 May 2026
Value US$186,348.08 | Price 29.36 | Shares 6,348
Proposed sale 12 May 2026
Value US$186,348.35 | Price 29.36 | Shares 6,348
Planned sale 11 May 2026
Value US$64,500.41 | Price 29.71 | Shares 2,171
Proposed sale 11 May 2026
Value US$64,500.41 | Price 29.71 | Shares 2,171
Planned sale 17 Apr 2026
Value US$13,033.28 | Price 31.33 | Shares 416
Proposed sale 17 Apr 2026
Value US$13,033.28 | Price 31.33 | Shares 416
Planned sale 15 Apr 2026
Value US$175,585.68 | Price 27.66 | Shares 6,348
Proposed sale 15 Apr 2026
Value US$175,585.68 | Price 27.66 | Shares 6,348
Planned sale 13 Apr 2026
Value US$373,086.67 | Price 26.54 | Shares 14,058
Proposed sale 13 Apr 2026
Value US$373,086.81 | Price 26.54 | Shares 14,058
Planned sale 13 Apr 2026
Value US$421,979.27 | Price 26.83 | Shares 15,730
Proposed sale 13 Apr 2026
Value US$421,979.55 | Price 26.83 | Shares 15,730
Planned sale 9 Apr 2026
Value US$59,414.60 | Price 27.38 | Shares 2,170
Proposed sale 9 Apr 2026
Value US$59,414.60 | Price 27.38 | Shares 2,170
Planned sale 31 Mar 2026
Value US$75,000.00 | Price 25.00 | Shares 3,000
Planned sale 31 Mar 2026
Value US$75,000.00 | Price 25.00 | Shares 3,000
Proposed sale 31 Mar 2026
Value US$75,000.00 | Price 25.00 | Shares 3,000
Planned sale 31 Mar 2026
Value US$12,254.15 | Price 27.05 | Shares 453
Planned sale 31 Mar 2026
Value US$1,464,474.05 | Price 26.54 | Shares 55,183
Planned sale 31 Mar 2026
Value US$493,793.62 | Price 25.50 | Shares 19,364
Proposed sale 31 Mar 2026
Value US$1,970,520.69 | Price 26.27 | Shares 75,000
Buy 30 Mar 2026
Value US$1,408,528.00 | Price 24.16 | Shares 58,300
Buy 27 Mar 2026
Value US$7,354,269.00 | Price 23.67 | Shares 310,700
Proposed sale 17 Mar 2026
Value US$10,696.05 | Price 25.65 | Shares 417
Planned sale 17 Mar 2026
Value US$10,696.05 | Price 25.65 | Shares 417
Planned sale 13 Mar 2026
Value US$7,038.46 | Price 27.82 | Shares 253
Planned sale 13 Mar 2026
Value US$84,264.53 | Price 27.37 | Shares 3,079
Planned sale 13 Mar 2026
Value US$277,922.46 | Price 25.91 | Shares 10,726
Proposed sale 13 Mar 2026
Value US$369,225.07 | Price 26.26 | Shares 14,058
Planned sale 12 Mar 2026
Value US$173,747.93 | Price 27.37 | Shares 6,348
Proposed sale 12 Mar 2026
Value US$173,748.15 | Price 27.37 | Shares 6,348
Planned sale 9 Mar 2026
Value US$58,269.64 | Price 26.84 | Shares 2,171
Proposed sale 9 Mar 2026
Value US$58,269.64 | Price 26.84 | Shares 2,171
Planned sale 17 Feb 2026
Value US$11,505.03 | Price 27.59 | Shares 417
Proposed sale 17 Feb 2026
Value US$11,505.03 | Price 27.59 | Shares 417
Planned sale 13 Feb 2026
Value US$175,100.06 | Price 27.58 | Shares 6,348
Planned sale 13 Feb 2026
Value US$113,856.78 | Price 27.33 | Shares 4,166
Planned sale 13 Feb 2026
Value US$96,775.53 | Price 27.33 | Shares 3,541
Proposed sale 13 Feb 2026
Value US$385,732.29 | Price 27.44 | Shares 14,055
Planned sale 12 Feb 2026
Value US$15,441.76 | Price 29.64 | Shares 521
Planned sale 12 Feb 2026
Value US$168,634.93 | Price 28.94 | Shares 5,828
Proposed sale 12 Feb 2026
Value US$184,076.52 | Price 28.99 | Shares 6,349
Planned sale 9 Feb 2026
Value US$65,585.91 | Price 30.21 | Shares 2,171
Proposed sale 9 Feb 2026
Value US$65,585.91 | Price 30.21 | Shares 2,171
Proposed sale 20 Jan 2026
Value US$13,353.60 | Price 32.10 | Shares 416
Planned sale 20 Jan 2026
Value US$13,353.60 | Price 32.10 | Shares 416
Planned sale 14 Jan 2026
Value US$370,644.91 | Price 32.61 | Shares 11,367
Proposed sale 14 Jan 2026
Value US$370,645.39 | Price 32.61 | Shares 11,367
Planned sale 13 Jan 2026
Value US$252,469.75 | Price 32.75 | Shares 7,709
Proposed sale 13 Jan 2026
Value US$252,469.75 | Price 32.75 | Shares 7,709
Planned sale 12 Jan 2026
Value US$205,143.24 | Price 32.32 | Shares 6,348
Proposed sale 12 Jan 2026
Value US$205,142.99 | Price 32.32 | Shares 6,348
Planned sale 12 Jan 2026
Value US$345,723.39 | Price 32.14 | Shares 10,758
Proposed sale 12 Jan 2026
Value US$345,722.93 | Price 32.14 | Shares 10,758
Planned sale 12 Jan 2026
Value US$235,932.11 | Price 33.15 | Shares 7,117
Planned sale 12 Jan 2026
Value US$293,707.49 | Price 32.21 | Shares 9,119
Proposed sale 12 Jan 2026
Value US$529,639.50 | Price 32.62 | Shares 16,236
Planned sale 9 Jan 2026
Value US$72,195.90 | Price 33.27 | Shares 2,170
Proposed sale 9 Jan 2026
Value US$72,195.90 | Price 33.27 | Shares 2,170
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-17 2026-06-17 PlS Planned sale
3.3
Karydas Daphne
Non-Executive Director
78,895 +48.0%
218.35
US$4,561,840 		78,895 +48.0% 218.35 US$4,561,840
2026-06-17 2026-06-17 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
10,195 +44.5%
205.02
US$887,240 		10,195 +44.5% 205.02 US$887,240
2026-06-17 2026-06-17 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
70,130
331.45
US$4,131,134 		70,130 331.45 US$4,131,134
2026-06-17 2026-06-17 PrS Proposed sale
3.3
Karydas Daphne

Officer

Officer
1,000
25.00
US$100,000 		1,000 25.00 US$100,000
2026-06-17 2026-06-15 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
1,000 -14.8%
23.81
US$100,000 		1,000 -14.8% 23.81 US$100,000
2026-06-15 2026-06-15 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
1,000
23.81
US$100,000 		1,000 23.81 US$100,000
2026-06-12 2026-06-12 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
1,000 -9.1%
23.93
US$100,000 		1,000 -9.1% 23.93 US$100,000
2026-06-12 2026-06-12 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
1,000
23.93
US$100,000 		1,000 23.93 US$100,000
2026-06-12 2026-06-12 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
1,000
23.93
US$100,000 		1,000 23.93 US$100,000
2026-06-12 2026-06-10 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
1,000 -3.3%
25.00
US$100,000 		1,000 -3.3% 25.00 US$100,000
2026-06-10 2026-06-10 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
1,000
25.00
US$100,000 		1,000 25.00 US$100,000
2026-05-19 2026-05-18 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
417 -0.7%
27.55
US$11,488 		417 -0.7% 27.55 US$11,488
2026-05-18 2026-05-18 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
417
27.55
US$11,488 		417 27.55 US$11,488
2026-05-18 2026-05-18 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
417
27.55
US$11,488 		417 27.55 US$11,488
2026-05-13 2026-05-13 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
14,056 -18.1%
28.58
US$401,789 		14,056 -18.1% 28.58 US$401,789
2026-05-13 2026-05-13 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
14,056
28.58
US$401,790 		14,056 28.58 US$401,790
2026-05-13 2026-05-12 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
6,348 -8.3%
29.36
US$186,348 		6,348 -8.3% 29.36 US$186,348
2026-05-12 2026-05-12 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
6,348
29.36
US$186,348 		6,348 29.36 US$186,348
2026-05-13 2026-05-11 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
2,171 -3.0%
29.71
US$64,500 		2,171 -3.0% 29.71 US$64,500
2026-05-11 2026-05-11 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
2,171
29.71
US$64,500 		2,171 29.71 US$64,500
2026-04-21 2026-04-17 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
416 -0.6%
31.33
US$13,033 		416 -0.6% 31.33 US$13,033
2026-04-17 2026-04-17 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
416
31.33
US$13,033 		416 31.33 US$13,033
2026-04-15 2026-04-15 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
6,348 -8.3%
27.66
US$175,586 		6,348 -8.3% 27.66 US$175,586
2026-04-15 2026-04-15 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
6,348
27.66
US$175,586 		6,348 27.66 US$175,586
2026-04-15 2026-04-13 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
14,058 -15.6%
26.54
US$373,087 		14,058 -15.6% 26.54 US$373,087
2026-04-15 2026-04-13 PlS Planned sale
3.5
Congleton Jon

Chief Executive Officer

Executive Director
15,730 -2.2%
26.83
US$421,979 		15,730 -2.2% 26.83 US$421,979
2026-04-13 2026-04-13 PrS Proposed sale
3.5
Congleton Jon

Officer

Officer
15,730
26.83
US$421,980 		15,730 26.83 US$421,980
2026-04-13 2026-04-13 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
14,058
26.54
US$373,087 		14,058 26.54 US$373,087
2026-04-13 2026-04-09 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
2,170 -2.8%
27.38
US$59,415 		2,170 -2.8% 27.38 US$59,415
2026-04-09 2026-04-09 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
2,170
27.38
US$59,415 		2,170 27.38 US$59,415
2026-04-02 2026-03-31 PlS Planned sale
3.3
Karydas Daphne
Non-Executive Director
3,000 -32.6%
25.00
US$75,000 		3,000 -32.6% 25.00 US$75,000
2026-04-02 2026-03-31 PlS Planned sale
3.3
Karydas Daphne
Non-Executive Director
3,000 -32.6%
25.00
US$75,000 		3,000 -32.6% 25.00 US$75,000
2026-04-02 2026-03-31 PlS Planned sale
3.5
Congleton Jon

Chief Executive Officer

Executive Director
453 -0.1%
27.05
US$12,254 		453 -0.1% 27.05 US$12,254
2026-04-02 2026-03-31 PlS Planned sale
3.5
Congleton Jon

Chief Executive Officer

Executive Director
55,183 -7.3%
26.54
US$1,464,474 		55,183 -7.3% 26.54 US$1,464,474
2026-04-02 2026-03-31 PlS Planned sale
3.5
Congleton Jon

Chief Executive Officer

Executive Director
19,364 -2.5%
25.50
US$493,794 		19,364 -2.5% 25.50 US$493,794
2026-03-31 2026-03-31 PrS Proposed sale
3.5
Congleton Jon

Officer

Officer
75,000
26.27
US$1,970,521 		75,000 26.27 US$1,970,521
2026-03-31 2026-03-31 PrS Proposed sale
3.3
Karydas Daphne

Officer

Officer
3,000
25.00
US$75,000 		3,000 25.00 US$75,000
2026-03-31 2026-03-30 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director
58,300 +1.0%
24.16
US$1,408,528 		58,300 +1.0% 24.16 US$1,408,528
2026-03-31 2026-03-27 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director
310,700 +5.7%
23.67
US$7,354,269 		310,700 +5.7% 23.67 US$7,354,269
2026-03-17 2026-03-17 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
417
25.65
US$10,696 		417 25.65 US$10,696
2026-03-17 2026-03-17 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
417 -0.5%
25.65
US$10,696 		417 -0.5% 25.65 US$10,696
2026-03-16 2026-03-13 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
253 -0.3%
27.82
US$7,038 		253 -0.3% 27.82 US$7,038
2026-03-16 2026-03-13 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
3,079 -3.9%
27.37
US$84,265 		3,079 -3.9% 27.37 US$84,265
2026-03-16 2026-03-13 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
10,726 -11.9%
25.91
US$277,922 		10,726 -11.9% 25.91 US$277,922
2026-03-13 2026-03-13 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
14,058
26.26
US$369,225 		14,058 26.26 US$369,225
2026-03-16 2026-03-12 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
6,348 -7.1%
27.37
US$173,748 		6,348 -7.1% 27.37 US$173,748
2026-03-12 2026-03-12 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
6,348
27.37
US$173,748 		6,348 27.37 US$173,748
2026-03-10 2026-03-09 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
2,171 -2.6%
26.84
US$58,270 		2,171 -2.6% 26.84 US$58,270
2026-03-09 2026-03-09 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
2,171
26.84
US$58,270 		2,171 26.84 US$58,270
2026-02-17 2026-02-17 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
417 -0.9%
27.59
US$11,505 		417 -0.9% 27.59 US$11,505
2026-02-17 2026-02-17 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
417
27.59
US$11,505 		417 27.59 US$11,505
2026-02-13 2026-02-13 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
6,348 -12.6%
27.58
US$175,100 		6,348 -12.6% 27.58 US$175,100
2026-02-13 2026-02-13 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
4,166 -7.6%
27.33
US$113,857 		4,166 -7.6% 27.33 US$113,857
2026-02-13 2026-02-13 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
3,541 -6.6%
27.33
US$96,776 		3,541 -6.6% 27.33 US$96,776
2026-02-13 2026-02-13 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
14,055
27.44
US$385,732 		14,055 27.44 US$385,732
2026-02-13 2026-02-12 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
521 -1.0%
29.64
US$15,442 		521 -1.0% 29.64 US$15,442
2026-02-13 2026-02-12 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
5,828 -10.3%
28.94
US$168,635 		5,828 -10.3% 28.94 US$168,635
2026-02-12 2026-02-12 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
6,349
28.99
US$184,077 		6,349 28.99 US$184,077
2026-02-11 2026-02-09 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
2,171 -4.1%
30.21
US$65,586 		2,171 -4.1% 30.21 US$65,586
2026-02-09 2026-02-09 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
2,171
30.21
US$65,586 		2,171 30.21 US$65,586
2026-01-20 2026-01-20 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
416
32.10
US$13,354 		416 32.10 US$13,354
2026-01-20 2026-01-20 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
416 -0.8%
32.10
US$13,354 		416 -0.8% 32.10 US$13,354
2026-01-15 2026-01-14 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
11,367 -18.4%
32.61
US$370,645 		11,367 -18.4% 32.61 US$370,645
2026-01-14 2026-01-14 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
11,367
32.61
US$370,645 		11,367 32.61 US$370,645
2026-01-15 2026-01-13 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
7,709 -11.1%
32.75
US$252,470 		7,709 -11.1% 32.75 US$252,470
2026-01-13 2026-01-13 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
7,709
32.75
US$252,470 		7,709 32.75 US$252,470
2026-01-13 2026-01-12 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
6,348 -9.3%
32.32
US$205,143 		6,348 -9.3% 32.32 US$205,143
2026-01-13 2026-01-12 PlS Planned sale
2.9
Levy Adam Scott

CFO and Secretary

Officer
10,758 -55.5%
32.14
US$345,723 		10,758 -55.5% 32.14 US$345,723
2026-01-13 2026-01-12 PlS Planned sale
3.5
Congleton Jon

Chief Executive Officer

Executive Director
7,117 -1.1%
33.15
US$235,932 		7,117 -1.1% 33.15 US$235,932
2026-01-13 2026-01-12 PlS Planned sale
3.5
Congleton Jon

Chief Executive Officer

Executive Director
9,119 -1.4%
32.21
US$293,707 		9,119 -1.4% 32.21 US$293,707
2026-01-12 2026-01-12 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
6,348
32.32
US$205,143 		6,348 32.32 US$205,143
2026-01-12 2026-01-12 PrS Proposed sale
2.9
Levy Adam Scott

Officer

Officer
10,758
32.14
US$345,723 		10,758 32.14 US$345,723
2026-01-12 2026-01-12 PrS Proposed sale
3.5
Congleton Jon

Officer; Director

Executive Director
16,236
32.62
US$529,640 		16,236 32.62 US$529,640
2026-01-13 2026-01-09 PlS Planned sale
3.5
Rodman David Malcom

Chief Medical Officer

Officer
2,170 -3.4%
33.27
US$72,196 		2,170 -3.4% 33.27 US$72,196
2026-01-09 2026-01-09 PrS Proposed sale
3.5
Rodman David Malcom

Officer

Officer
2,170
33.27
US$72,196 		2,170 33.27 US$72,196
Explore more

More insider trading research around Mineralys Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America